期刊文献+

阿托伐他汀联合卡格列净治疗中心性肥胖2型糖尿病的临床研究

Clinical study of atorvastatin combined with cagelin in the treatment of central obesity type 2 diabetes
下载PDF
导出
摘要 目的研究阿托伐他汀联合卡格列净治疗中心性肥胖2型糖尿病(T2DM)的临床疗效。方法选择浙江省绍兴市中医院2019年9月~2021年1月中心性肥胖T2DM患者82例,按随机数字表法分为阿托伐他汀组和联合卡格列净组,每组41例。阿托伐他汀组给予阿托伐他汀口服治疗,20mg/次,1次/d;联合卡格列净组在阿托伐他汀组的基础上加用卡格列净口服治疗,10mg/次,1次/d。两组均连续治疗12周。比较两组治疗前后肥胖相关指标(BMI、腰围)、炎性因子(CRP、TNF-α、IL-6)、糖代谢指标(FBG、2hPG、HbA1c、FINS)、脂代谢指标(TC、TG、LDL-C、HDL-C)及同型半胱氨酸(Hcy)水平。结果治疗12周后,两组BMI、腰围、CRP、TNF-α、IL-6、FBG、2hPG、HbA1c、FINS、TC、TG、LDL-C、Hcy均显著降低(均P<0.05),且联合卡格列净组更低(P<0.01);HDL-C显著升高(P<0.05),且联合卡格列净组更高(P<0.01)。结论阿托伐他汀联合卡格列净可有效控制中心性肥胖T2DM患者肥胖程度,改善糖代谢和脂代谢。 Objective To study the clinical efficacy of atorvastatin combined with cagelin in the treatment of central obesity type 2 diabetes mellitus(T2DM).Method 82 patients with central obesity type 2 diabetes mellitus(T2DM)from September 2019 to January 2021 at Shaoxing Traditional Chinese Medicine Hospital in Zhejiang Province were selected and randomly divided into atorvastatin group and combined canagliflozin group,with 41 patients in each group.The atorvastatin group received oral treatment with atorvastatin,20mg/time,once a day;The combination therapy of canagliflozin and atorvastatin was supplemented with oral canagliflozin at a dose of 10mg/time,once a day.Result Both groups received continuous treatment for 12 weeks.Compare obesity related indicators(BMI,waist circumference),inflammatory factors(CRP,TNF-α,IL-6),glucose metabolism indicators(FBG,2hPG,HbA1c,FINS),lipid metabolism indicators(TC,TG,LDL-C,HDL-C),and homocysteine(Hcy)levels between two groups before and after treatment.After 12 weeks of treatment,BMI,waist circumference,CRP,TNF-α,IL-6,FBG,2hPG,HbA1c,FINS,TC,TG,LDL-C and Hcy were significantly reduced in both groups(all P<0.05),and the group combined with canagliflozin had even lower levels(P<0.01);HDL-C was significantly elevated(P<0.05),and the combination group with canagliflozin had even higher levels(P<0.01).Conclusion Atorvastatin combined with canagliflozin can effectively control the degree of obesity and improve glucose and lipid metabolism in T2DM patients with central obesity.
作者 肖勇 陈可为 王天舒 XIAO Yong;CHEN Kewei;WANG Tianshu(Shaoxing Traditional Chinese Medicine Hospital,Shaoxing 312400,China)
机构地区 绍兴市中医院
出处 《浙江实用医学》 2024年第5期371-374,共4页 Zhejiang Practical Medicine
关键词 2型糖尿病 中心性肥胖 卡格列净 阿托伐他汀 糖脂代谢 炎性因子 HCY type 2 diabetes central obesity kagliflozin atorvastatin glucose and lipid metabolism inflammatory factors Hcy
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部